Caliper Launches Xenogen In Vivo Imaging System
Complete the form below to unlock access to ALL audio articles.
Caliper Life Sciences, Inc. has unveiled the Xenogen IVIS Spectrum, addition to the company's suite of in vivo imaging systems, at the Fifth Annual Meeting of the Society for Molecular Imaging (SMI) on the Big Island of Hawaii.
The next generation of instrumentation in optical imaging, the IVIS Spectrum is the in vivo optical imaging system that is designed to perform high sensitivity bioluminescent imaging and advanced fluorescent imaging, including spectral unmixing, trans-illumination, and 3D tomographic capabilities.
With an optical switch to move from epi- (reflection or top illumination) to trans-illumination (bottom illumination), IVIS Spectrum maintains high throughput capability, while providing increased sensitivity in fluorescent imaging.
This dual illumination capability enables tomographic localization of both shallow and deep tumors in 3D and reduces background interference.
Spectral unmixing, using discrete bandpass filters, reduces background autofluorescence and allows separation of multiple reporters.
"Caliper is committed to pioneering highly innovative and transformative technologies that meet the needs of the research and development community," said Kevin Hrusovsky, president and CEO of Caliper.
"The IVIS Spectrum is a translational tool that enables both superior fluorescent and bioluminescent capabilities and is designed to improve productivity and clinical relevancy through the entire continuum of drug discovery."
Illuminating biological processes allows real-time visual exploration and analysis of gene expression, cellular pathways, drug/target interactions and the mechanism of action of drugs.
The system is designed to enable researchers to accurately pinpoint where and when a drug candidate has an effect on or is affected by a normal or disease process.
